Fig. 1: Cumulative incidence of SARS-CoV-2 infection, hospitalization due to COVID-19, and overall survival among individuals with monoclonal B cell lymphocytosis (MBL) compared to those without MBL (i.e., with normal immunophenotype [NIPT]). | Blood Cancer Journal

Fig. 1: Cumulative incidence of SARS-CoV-2 infection, hospitalization due to COVID-19, and overall survival among individuals with monoclonal B cell lymphocytosis (MBL) compared to those without MBL (i.e., with normal immunophenotype [NIPT]).

From: The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis

Fig. 1

a Cumulative incidence of contracting SARS-CoV-2 adjusted for the competing risk of death in individuals with monoclonal B cell lymphocytosis (MBL) compared to individuals without MBL (normal immunophenotype [NIPT]). b Cumulative incidence of COVID-19 infection-related hospitalizations adjusted for the competing risk of death among subjects with monoclonal B cell lymphocytosis (MBL) compared to individuals without MBL (normal immunophenotype [NIPT]). c Overall survival of all study participants grouped according to monoclonal B cell lymphocytosis (MBL) or no MBL (normal immunophenotype [NIPT]) at study entry.

Back to article page